secwatch.observer — SEC 8-K summary
======================================

Issuer:     TFF Pharmaceuticals, Inc. (—)
CIK:        0001733413
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0001213900-23-096633
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive interim Phase 2 data for TFF VORI and TFF TAC; company to accelerate to registration-enabling studies
--------------------------------------------------------------------------------

- All five TFF VORI patients achieved clinical and mycologic responses; no all-cause mortality or discontinuations due to AEs.
- All four TFF TAC patients transitioned from oral tacrolimus with reduced blood levels; no acute rejection; kidney function maintained.
- Company plans to accelerate initiation of registration-enabling studies for both TFF VORI and TFF TAC.
- 1-for-25 reverse stock split effective December 19, reducing shares from ~59M to ~2.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/0001213900-23-096633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/ea190285-8k_tffpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-096633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer